Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ:SRRK) has been assigned a consensus recommendation of “Buy” from the seventeen ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and four have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $51.1429.

Several equities research analysts have recently weighed in on SRRK shares. Bank of America initiated coverage on shares of Scholar Rock in a research note on Thursday, October 9th. They set a “buy” rating and a $53.00 target price for the company. Citigroup initiated coverage on Scholar Rock in a research report on Friday, January 9th. They set a “buy” rating and a $55.00 price objective for the company. HC Wainwright lifted their target price on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Barclays upped their price target on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Finally, UBS Group assumed coverage on shares of Scholar Rock in a research report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock.

Insiders Place Their Bets

In other news, CEO David Hallal sold 57,450 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $2,453,115.00. Following the completion of the transaction, the chief executive officer directly owned 1,541,645 shares of the company’s stock, valued at approximately $65,828,241.50. This represents a 3.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jing L. Marantz sold 5,798 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $44.48, for a total value of $257,895.04. Following the completion of the sale, the insider directly owned 95,687 shares of the company’s stock, valued at $4,256,157.76. This represents a 5.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 305,687 shares of company stock valued at $13,540,573. Corporate insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Scholar Rock by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock worth $228,860,000 after purchasing an additional 280,538 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Scholar Rock by 124.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after purchasing an additional 2,521,022 shares in the last quarter. Bellevue Group AG lifted its stake in shares of Scholar Rock by 10.1% in the third quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock valued at $120,827,000 after purchasing an additional 297,242 shares during the period. Eventide Asset Management LLC boosted its holdings in Scholar Rock by 9.5% during the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company’s stock worth $103,192,000 after buying an additional 251,638 shares in the last quarter. Finally, Jennison Associates LLC grew its position in Scholar Rock by 74.0% during the fourth quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock worth $123,128,000 after buying an additional 1,188,676 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Stock Performance

Shares of SRRK opened at $44.34 on Friday. The company’s 50 day simple moving average is $44.27 and its 200-day simple moving average is $37.54. The firm has a market cap of $4.52 billion, a PE ratio of -14.08 and a beta of 0.63. Scholar Rock has a 12-month low of $22.71 and a 12-month high of $48.28. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the previous year, the business posted ($0.66) EPS. As a group, equities analysts predict that Scholar Rock will post -2.42 EPS for the current year.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).